(Q30341330)

20 June 2017

1 reference

title

Genetic variability in CYP3A5 and its possible consequences. (English)

1 reference

20 June 2017

Hong-Guang Xie

1

1 reference

20 June 2017

Alastair J J Wood

2

1 reference

20 June 2017

Richard B Kim

3

1 reference

20 June 2017

C Michael Stein

4

1 reference

20 June 2017

Grant R Wilkinson

5

1 reference

20 June 2017

publication date

1 April 2004

1 reference

20 June 2017

1 reference

20 June 2017

volume

5

1 reference

20 June 2017

issue

3

1 reference

20 June 2017

page(s)

243-272

1 reference

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

20 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

CYP3A gene expression in human gut epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Expression of cytochrome P450 3A in amphibian, rat, and human kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The role of individual human cytochromes P450 in drug metabolism and clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Substrates of human hepatic cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Cytochrome P-450 3A4: regulation and role in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The human CYP3A subfamily: practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Summary of information on human CYP enzymes: human P450 metabolism data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

In vitro and pharmacophore insights into CYP3A enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The human cytochrome P450 CYP3 locus: assignment to chromosome 7q22-qter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Intergenic mRNA molecules resulting from trans-splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

CYP3A5 phenotype-genotype correlations in a British population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Sequence of the 5'-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Apparent low frequency of sequence variability within the proximal promoter region of the cytochrome P450 (CYP) 3A5 gene in established cell lines from Japanese individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Regulation of cyp3a gene transcription by the pregnane x receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Molecular basis of ethnic differences in drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Inheritance and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Medical practice, race, and drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The importance of race and ethnic background in biomedical research and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Genetics. FDA races in wrong direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Use of race and ethnicity in biomedical publication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Race, distributive justice and the promise of pharmacogenomics: ethical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

CYP2C9 allelic variants: ethnic distribution and functional significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Meta-analysis: a method for synthesizing research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Transporters and xenobiotic disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Transporter-Enzyme Interactions: Implications for Predicting Drug-Drug Interactions from In Vitro Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

A perfect message: RNA surveillance and nonsense-mediated decay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

mRNA surveillance in mammalian cells: the relationship between introns and translation termination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

An mRNA surveillance mechanism that eliminates transcripts lacking termination codons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

A significant drug-metabolizing role for CYP3A5?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Ethnic differences in the pharmacokinetics of oral nifedipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

CYP3A activity in European American and Japanese men using midazolam as an in vivo probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Racial variation in dosage requirements of tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Human population structure and genetic association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Expression and localization of CYP3A4 and CYP3A5 in human lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

CYP3A5*1 is an inhibitory factor for lung cancer in Taiwanese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.5.3.243.29833

10.1517/PHGS.5.3.243.29833

21 January 2018

Identifiers

DOI

1 reference

20 June 2017

1 reference